MY195904A - Indolinones Compounds and Their use in the Treatment Of Fibrotic Diseases - Google Patents

Indolinones Compounds and Their use in the Treatment Of Fibrotic Diseases

Info

Publication number
MY195904A
MY195904A MYPI2018001087A MYPI2018001087A MY195904A MY 195904 A MY195904 A MY 195904A MY PI2018001087 A MYPI2018001087 A MY PI2018001087A MY PI2018001087 A MYPI2018001087 A MY PI2018001087A MY 195904 A MY195904 A MY 195904A
Authority
MY
Malaysia
Prior art keywords
treatment
compounds
fibrotic diseases
indolinones
compositions
Prior art date
Application number
MYPI2018001087A
Other languages
English (en)
Inventor
Iain Walter
Louise Birch
Joseph Hill-Cousins
Stephen Paul Collingwood
Christopher Scott Stevenson
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of MY195904A publication Critical patent/MY195904A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2018001087A 2015-12-24 2016-12-23 Indolinones Compounds and Their use in the Treatment Of Fibrotic Diseases MY195904A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202764 2015-12-24
PCT/GB2016/054069 WO2017109513A1 (en) 2015-12-24 2016-12-23 Indolinones compounds and their use in the treatment of fibrotic diseases

Publications (1)

Publication Number Publication Date
MY195904A true MY195904A (en) 2023-02-27

Family

ID=55068868

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001087A MY195904A (en) 2015-12-24 2016-12-23 Indolinones Compounds and Their use in the Treatment Of Fibrotic Diseases

Country Status (30)

Country Link
US (1) US11046672B2 (enExample)
EP (2) EP3722291B1 (enExample)
JP (1) JP7068172B2 (enExample)
KR (1) KR20180128390A (enExample)
CN (1) CN109302846B (enExample)
AU (1) AU2016376011B2 (enExample)
BR (1) BR112018013033A2 (enExample)
CA (1) CA3009778A1 (enExample)
CL (1) CL2018001742A1 (enExample)
CO (1) CO2018007663A2 (enExample)
CY (1) CY1126258T1 (enExample)
DK (1) DK3722291T3 (enExample)
EA (1) EA038796B1 (enExample)
ES (2) ES2956820T3 (enExample)
FI (1) FI3722291T3 (enExample)
HR (1) HRP20230833T1 (enExample)
HU (1) HUE062784T2 (enExample)
IL (1) IL260221A (enExample)
LT (1) LT3722291T (enExample)
MX (1) MX379859B (enExample)
MY (1) MY195904A (enExample)
PH (1) PH12018501575A1 (enExample)
PL (1) PL3722291T3 (enExample)
PT (1) PT3722291T (enExample)
RS (1) RS64703B1 (enExample)
SG (1) SG11201805423TA (enExample)
SI (1) SI3722291T1 (enExample)
SM (1) SMT202300260T1 (enExample)
WO (1) WO2017109513A1 (enExample)
ZA (1) ZA201804950B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
JP7039480B2 (ja) * 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
CN109678810B (zh) * 2019-01-23 2022-10-28 南京工业大学 一种1,2-氧氮杂环丁烷类化合物及其制备方法与应用
EP4061373A4 (en) * 2019-11-20 2023-11-15 Angion Biomedica Corp. METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE
CN111789842B (zh) * 2020-08-07 2021-09-21 南开大学 尼达尼布在制备用于治疗炎症性肠病的药物中的应用
KR102739882B1 (ko) * 2021-04-02 2024-12-06 연세대학교 원주산학협력단 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물
CN113200936B (zh) * 2021-05-19 2022-10-21 南京工业大学 10-甲基吩噁嗪衍生物、其锆金属有机框架材料及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2004182726A (ja) 2002-11-22 2004-07-02 Yamanouchi Pharmaceut Co Ltd 2−オキソインドリン誘導体
US20060154939A1 (en) 2004-12-24 2006-07-13 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2602389A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Kinase inhibitors
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
JP7039480B2 (ja) 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用

Also Published As

Publication number Publication date
EP3722291A1 (en) 2020-10-14
HUE062784T2 (hu) 2023-12-28
IL260221A (en) 2018-07-31
PH12018501575A1 (en) 2019-04-15
CO2018007663A2 (es) 2018-10-10
US11046672B2 (en) 2021-06-29
PT3722291T (pt) 2023-09-22
DK3722291T3 (da) 2023-09-18
MX379859B (es) 2025-03-11
CN109302846B (zh) 2021-05-11
MX2018007852A (es) 2018-11-09
EP3722291B1 (en) 2023-07-19
FI3722291T3 (fi) 2023-09-05
HRP20230833T1 (hr) 2023-11-10
BR112018013033A2 (pt) 2018-12-04
WO2017109513A1 (en) 2017-06-29
ES2796358T3 (es) 2020-11-26
SG11201805423TA (en) 2018-07-30
PL3722291T3 (pl) 2023-11-27
JP7068172B2 (ja) 2022-05-16
CL2018001742A1 (es) 2018-11-23
SI3722291T1 (sl) 2023-10-30
EP3394048A1 (en) 2018-10-31
CN109302846A (zh) 2019-02-01
CA3009778A1 (en) 2017-06-29
LT3722291T (lt) 2023-12-11
SMT202300260T1 (it) 2023-09-06
EA201891506A1 (ru) 2019-02-28
AU2016376011B2 (en) 2021-02-11
CY1126258T1 (el) 2026-02-25
ZA201804950B (en) 2020-11-25
KR20180128390A (ko) 2018-12-03
RS64703B1 (sr) 2023-11-30
US20190337929A1 (en) 2019-11-07
ES2956820T3 (es) 2023-12-28
AU2016376011A1 (en) 2018-08-09
EP3394048B1 (en) 2020-03-11
EA038796B1 (ru) 2021-10-20
JP2019501910A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
PH12018501575A1 (en) Indolinones compounds and their use in the treatment of fibrotic diseases
PH12018500457A1 (en) New phenoxymethyl derivatives
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
MX2017014035A (es) Formas solidas novedosas.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12016501807A1 (en) Novel compounds
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
TN2017000031A1 (en) Imidazopyridazine compounds
MX2016009760A (es) Inhibidores de neprilisina.
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
PH12017501133A1 (en) Pyrazolopyridinamines
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
EA201791174A1 (ru) Антимикотическое соединение
PH12016501932A1 (en) Amido-substituted azole compounds
EA201790613A8 (ru) Триазольные соединения в качестве блокаторов кальциевых каналов т-типа
MX2020001199A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
MX371158B (es) Compuestos inhibidores de pde2.